Health Care • Biotechnology: Pharmaceutical Preparations
$12.27 ▼ -0.81
(-6.19%)
MKT CAP: $3.97B • VOL: 3.88M
52W L $3 52W H $15
ABCL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $75.1M | $28.8M | $38.0M |
| YoY Revenue Growth % | +160.6% | -24.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$217.1M | -$314.8M | -$237.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$146.4M | -$162.9M | -$146.4M |
| EBITDA (Normalized) | -$182.9M | -$252.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$131.3M | -$108.6M | -$43.9M |
| Capital Expenditures (CapEx) | $42.8M | $78.4M | — |
| Free Cash Flow (FCF) | -$174.1M | -$187.0M | -$43.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -20.5% | -27.6% | — |
| Cash & Short-Term Equivalents | $128.5M | $156.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $966.9M | $1.06B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABCL.